“If we don’t include women in trials, we are not protecting women” – dolutegravir in pregnant women living with HIV
Black people and women are under-represented in anti-HIV drug studies
Adherence clubs linked to 30% reduction in high viral load among postpartum South African women living with HIV
Dolutegravir-based HIV treatment is the safest and most effective choice for pregnant women
Babies of South African mothers taking HIV therapy have worse health in early months – unless they are vaccinated and consistently breastfed
ADVANCE study shows high frequency of major weight gain in women receiving dolutegravir with TAF
Weight gain on HIV treatment: drug combinations, not single drugs, need to be focus of quest for cause
Neural tube defects and integrase inhibitors: still waiting for stronger evidence
Integrase inhibitors give greater chance of viral suppression at delivery in pregnant women
